Welcome to our dedicated page for Intuitive Surgical news (Ticker: ISRG), a resource for investors and traders seeking the latest updates and insights on Intuitive Surgical stock.
Intuitive Surgical, Inc. (ISRG) is a medical technology company headquartered in Sunnyvale, California and known for its role in minimally invasive care and robotic-assisted surgery. Its news flow frequently centers on developments related to the da Vinci surgical systems and the Ion endoluminal system, along with financial performance updates and regulatory milestones.
Investors and healthcare professionals following ISRG news can expect regular earnings announcements, where the company reports quarterly and preliminary annual financial results. These updates typically highlight worldwide procedure growth on da Vinci and Ion platforms, changes in the installed base of systems, and trends in systems, instruments, and accessories revenue.
Another major category of Intuitive news involves product clearances and platform enhancements. Recent press releases describe FDA clearances expanding indications for the da Vinci Single Port (SP) system to additional general surgery procedures, clearance of advanced energy instruments such as Vessel Sealer Curved, and regulatory certifications for the da Vinci 5 system in regions including the European Union and Japan. News also covers software and digital features for da Vinci 5, such as Force Gauge, In-Console Video Replay, and Network CCM for remote software updates.
Intuitive’s news feed also includes updates on the Ion endoluminal system, including FDA-cleared software releases that introduce artificial intelligence across Ion’s navigational workflow and integrate advanced imaging capabilities to support lung biopsy procedures. Additional stories describe demonstrations of telesurgery capabilities using da Vinci 5 and collaborations with hospitals adopting newer platforms.
For those tracking ISRG, this news page provides a consolidated view of company press releases, allowing readers to monitor procedure and system trends, regulatory progress, and technology updates that shape Intuitive’s position in robotic-assisted surgery and minimally invasive care.
Intuitive (NASDAQ: ISRG) has published two peer-reviewed studies in Surgical Endoscopy demonstrating the effectiveness of its Force Feedback technology in the da Vinci 5 surgical system. The first study, led by Dr. Michael M. Awad, showed that the technology can reduce force on tissue by up to 43% across all surgeon experience levels.
The second study, led by Dr. Andrew J. Hung, revealed that Force Feedback technology significantly improves novice surgeon performance, reducing tissue trauma and errors during suturing. The research involved 28 surgeons in the first study and 29 novice surgeons in the second study, all conducted in pre-clinical settings using tissue models.
The technology is currently available in U.S. hospitals, with plans for expanded availability through 2025 and beyond.
Intuitive (NASDAQ:ISRG) has announced a $45 million donation to the Intuitive Foundation, bringing total contributions to over $170 million since 2018. The Foundation focuses on reducing global disease burden through philanthropy, research, and education for better patient outcomes.
In 2024, the Foundation matched employee donations with over $7 million supporting 2,000+ causes, provided $6 million in research grants and surgical fellowships, and contributed $3 million to the Surgical Education Learners Forum. Key programs include the Global Surgical Training Challenge, supporting FIRST Robotics teams globally, and the Surgical Education Learners Forum (SELF), which develops free training modules for clinicians in low-resource settings.
Intuitive (ISRG) reported strong Q4 2024 financial results with revenue reaching $2.41 billion, up 25% from Q4 2023. The company's worldwide da Vinci procedures grew 18% year-over-year, while system placements increased to 493 units, including 174 da Vinci 5 systems. The installed base expanded to 9,902 systems, marking a 15% increase from the previous year.
GAAP net income rose to $686 million ($1.88 per diluted share), compared to $606 million ($1.69 per diluted share) in Q4 2023. Non-GAAP net income reached $805 million ($2.21 per diluted share). The company ended Q4 with $8.83 billion in cash and investments.
For 2025 outlook, Intuitive expects worldwide da Vinci procedures to grow 13-16%, with non-GAAP gross profit margin projected between 67-68% and operating expense growth of 10-15%.
Intuitive (NASDAQ:ISRG) has announced plans to establish a direct presence in Italy, Spain, Portugal, Malta, and San Marino through the acquisition of da Vinci and Ion distribution businesses in these regions. The company has entered into agreements with current distributors ab medica, Abex, Excelencia Robotica, and their affiliates.
The transaction is subject to regulatory approvals and is expected to close in 2026. Upon closure, the distribution businesses will be fully integrated into Intuitive's European commercial and marketing organization, led by Senior VP and General Manager Dirk Barten. The move aims to deepen understanding of customer needs and expand access to minimally invasive care in these markets.
Intuitive (ISRG) reported strong preliminary Q4 and full-year 2024 results. Q4 revenue reached $2.41 billion, up 25% year-over-year, while full-year 2024 revenue grew 17% to $8.35 billion. The company placed 493 da Vinci surgical systems in Q4 2024, including 174 da Vinci 5 systems, marking a 19% increase from Q4 2023.
Worldwide da Vinci procedures grew approximately 18% in Q4 and 17% for the full year 2024, reaching approximately 2,683,000 procedures. Growth was driven by a 19% increase in U.S. general surgery procedures and 23% growth in procedures outside the U.S. The company projects worldwide da Vinci procedures to increase 13-16% in 2025.
Q4 instruments and accessories revenue increased 23% to $1.41 billion, while systems revenue grew 36% to $655 million. The company noted no significant COVID-19 disruptions during 2024.
Intuitive (NASDAQ:ISRG) announced three executive leadership promotions to support its global growth strategy. Henry Charlton has been promoted to Executive Vice President and Chief Commercial and Marketing Officer, bringing 21 years of experience across various leadership roles. Gary Loeb has been elevated to Executive Vice President and Chief Legal and Compliance Officer, having joined in 2022 as SVP and General Counsel. Jamie Samath has been promoted to Executive Vice President, Chief Financial Officer and Enterprise Technology Leader, expanding his role since joining in 2013.
These promotions aim to strengthen Intuitive's leadership team as it continues its mission in advancing minimally invasive care. The company, which pioneered robotic-assisted surgery with its da Vinci system, has facilitated over 15 million procedures globally and trained more than 76,000 surgeons worldwide.
A comprehensive meta-analysis published in Annals of Surgery has demonstrated significant benefits of da Vinci robotic surgery compared to laparoscopic and open surgical approaches. The study analyzed 230 studies from 22 countries over 12 years, including randomized controlled trials, prospective studies, and database reviews.
Key findings show that da Vinci robotic cases were 56% less likely to convert to open surgery versus laparoscopy, experienced 21% fewer blood transfusions versus laparoscopy and 75% versus open, and had 10% fewer 30-day postop complications versus laparoscopy and 44% versus open. Patients also experienced shorter hospital stays, though operative times were longer than both traditional approaches.
Intuitive (ISRG) reported strong financial results for Q3 2024. Key highlights include:
- Worldwide da Vinci procedures grew 18% year-over-year
- 379 da Vinci surgical systems placed, up from 312 in Q3 2023
- Installed base increased 15% to 9,539 systems
- Revenue rose 17% to $2.04 billion
- GAAP net income of $565 million ($1.56 per diluted share)
- Non-GAAP net income of $669 million ($1.84 per diluted share)
The company saw growth in da Vinci procedure volume and system placements. Instruments and accessories revenue increased 18%, while systems revenue grew significantly. Intuitive ended the quarter with $8.31 billion in cash and investments.
Jupiter Endovascular, a medical technology startup, has exited stealth mode with $21 million in new financing to fund a pivotal trial for Pulmonary Embolism. The company is developing a new class of endovascular procedures using Endoportal Control™ technology, which aims to bring the precision of direct surgical access to catheter-based interventions. Carl J. St. Bernard has been appointed as CEO, bringing over 30 years of experience in the life sciences industry.
The funding round, led by Sonder Capital with participation from strategic investors, will support the upcoming pivotal trial and development of additional clinical applications. Jupiter's technology addresses limitations in catheter-based therapies by providing stability and control within complex cardiovascular anatomies, potentially revolutionizing treatment for millions of patients worldwide.
Neptune Medical, a medical device innovator, has announced a successful $97 million Series D financing and the spinout of its subsidiary, Jupiter Endovascular. The financing round saw significant participation from Sonder Capital and Olympus of the Americas, along with other existing and new investors. This strategic move allows Neptune Medical to focus on gastrointestinal robotics, while Jupiter Endovascular will concentrate on its novel endovascular technology platform.
The financing will strengthen Neptune Medical's position in the GI space, as evidenced by the recent appointment of Dr. Fred Moll, a medical robotics pioneer, as Chairman of the Board. Both companies aim to lead innovation in their respective specialties, with Neptune pushing boundaries in GI robotics and Jupiter revolutionizing endovascular therapies.
FAQ
What is the current stock price of Intuitive Surgical (ISRG)?
What is the market cap of Intuitive Surgical (ISRG)?
